Yun Su Eun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yun Su Eun has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Jung Eun Kim
Department of Dermatology, Soonchunhyang University Cheonan Hospital, Soonchunhyang University College of Medicine, Cheonan, Korea
5 shared publications - Jae Yun Kim
Department of Dermatology Soonchunhyang University Cheonan Hospital Cheonan South Korea
4 shared publications - Sung Yul Lee
Department of Dermatology, Soonchunhyang University Cheonan Hospital, Soonchunhyang University College of Medicine, Cheonan, Korea
4 shared publications - Euy Hyun Chung
Department of Dermatology, Soonchunhyang University Cheonan Hospital, Soonchunhyang University College of Medicine, Cheonan, Korea
3 shared publications - Na Gyeong Yang
Department of Dermatology, College of Medicine, Soonchunhyang University Cheonan Hospital, Cheonan 31151, Republic of Korea
3 shared publications - Whiin Lee
Department of Dermatology, Soonchunhyang University Cheonan Hospital, Soonchunhyang University College of Medicine, Cheonan, Korea
3 shared publications
Latest Publications
- Open Access
- 31 December 2025
- Published by The Korean Society for Psoriasis in Journal of the Korean Society for Psoriasis
- Vol. 22 (2) , 70-74
Biologic switching in psoriasis: from evidence to practice
Yun Su Eun, Euy Hyun Chung. Journal of the Korean Society for Psoriasis 2025;22:70-4. https://doi.org/10.23203/JKSP.2025.22.2.70
- 31 December 2025
- Published by The Korean Society for Psoriasis in Journal of the Korean Society for Psoriasis
- Vol. 22 (2) , 70-74
Open AccessBiologic switching in psoriasis: from evidence to practice
Yun Su Eun, Euy Hyun Chung. Journal of the Korean Society for Psoriasis 2025;22:70-4. https://doi.org/10.23203/JKSP.2025.22.2.70
- Open Access
- 30 May 2024
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 23 (10) , 3432-3433
Successful treatment of cutaneous siderosis using a 1064‐nm Nd:YAG picosecond laser following intravenous iron extravasation: A case report
- 30 May 2024
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 23 (10) , 3432-3433
Open AccessSuccessful treatment of cutaneous siderosis using a 1064‐nm Nd:YAG picosecond laser following intravenous iron extravasation: A case report
- Open Access
- 31 March 2024
- Published by Korean Society for Medical Mycology in Korean Journal of Medical Mycology
- p. 33-35
A Case of Cheilocandidosis Involving the Upper and Lower Lips
Journal of mycology and infection (Acronym: JMI, Abbreviation: J Mycol Infect) aims to publish articles of exceptional interests in the field of medical mycology. The journal originally was launched in 1996 as the Korean Journal of Medical Mycology and has reformed into the current state beginning on March of 2018. The contents of the journal should elucidate important microbiological fundamentals and provide qualitative insights to respective clinical aspects. JMI underlines the submission of novel findings and studies in clinical mycology that are enriched by analyses achieved through investigative methods.
- 31 March 2024
- Published by Korean Society for Medical Mycology in Korean Journal of Medical Mycology
- p. 33-35
Open AccessA Case of Cheilocandidosis Involving the Upper and Lower Lips
Journal of mycology and infection (Acronym: JMI, Abbreviation: J Mycol Infect) aims to publish articles of exceptional interests in the field of medical mycology. The journal originally was launched in 1996 as the Korean Journal of Medical Mycology and has reformed into the current state beginning on March of 2018. The contents of the journal should elucidate important microbiological fundamentals and provide qualitative insights to respective clinical aspects. JMI underlines the submission of novel findings and studies in clinical mycology that are enriched by analyses achieved through investigative methods.
- Open Access
- 21 December 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (1) , 167
Mechanistic Investigation of WWOX Function in NF-kB-Induced Skin Inflammation in Psoriasis
Psoriasis is a chronic inflammatory skin disease characterized by epidermal hyperproliferation, aberrant differentiation of keratinocytes, and dysregulated immune responses. WW domain-containing oxidoreductase (WWOX) is a non-classical tumor suppressor gene that regulates multiple cellular processes, including proliferation, apoptosis, and migration. This study aimed to explore the possible role of WWOX in the pathogenesis of psoriasis. Immunohistochemical analysis showed that the expression of WWOX was increased in epidermal keratinocytes of both human psoriatic lesions and imiquimod-induced mice psoriatic model. Immortalized human epidermal keratinocytes were transduced with a recombinant adenovirus expressing microRNA specific for WWOX to downregulate its expression. Inflammatory responses were detected using Western blotting, real-time quantitative reverse transcription polymerase chain reaction (PCR), and enzyme-linked immunosorbent assay. In human epidermal keratinocytes, WWOX knockdown reduced nuclear factor-kappa B signaling and levels of proinflammatory cytokines induced by polyinosinic: polycytidylic acid [(poly(I:C)] in vitro. Furthermore, calcium chelator and protein kinase C (PKC) inhibitors significantly reduced poly(I:C)-induced inflammatory reactions. WWOX plays a role in the inflammatory reaction of epidermal keratinocytes by regulating calcium and PKC signaling. Targeting WWOX could be a novel therapeutic approach for psoriasis in the future.
- 21 December 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (1) , 167
Open AccessMechanistic Investigation of WWOX Function in NF-kB-Induced Skin Inflammation in Psoriasis
Psoriasis is a chronic inflammatory skin disease characterized by epidermal hyperproliferation, aberrant differentiation of keratinocytes, and dysregulated immune responses. WW domain-containing oxidoreductase (WWOX) is a non-classical tumor suppressor gene that regulates multiple cellular processes, including proliferation, apoptosis, and migration. This study aimed to explore the possible role of WWOX in the pathogenesis of psoriasis. Immunohistochemical analysis showed that the expression of WWOX was increased in epidermal keratinocytes of both human psoriatic lesions and imiquimod-induced mice psoriatic model. Immortalized human epidermal keratinocytes were transduced with a recombinant adenovirus expressing microRNA specific for WWOX to downregulate its expression. Inflammatory responses were detected using Western blotting, real-time quantitative reverse transcription polymerase chain reaction (PCR), and enzyme-linked immunosorbent assay. In human epidermal keratinocytes, WWOX knockdown reduced nuclear factor-kappa B signaling and levels of proinflammatory cytokines induced by polyinosinic: polycytidylic acid [(poly(I:C)] in vitro. Furthermore, calcium chelator and protein kinase C (PKC) inhibitors significantly reduced poly(I:C)-induced inflammatory reactions. WWOX plays a role in the inflammatory reaction of epidermal keratinocytes by regulating calcium and PKC signaling. Targeting WWOX could be a novel therapeutic approach for psoriasis in the future.
- Open Access
- 1 January 2023
- Published by Wiley in Dermatologic Therapy
- Vol. 2023 (1)
A Novel, Hand‐Held, and Low‐Level Light Therapy Device for the Treatment of Acne Vulgaris: A Single‐Arm, Prospective Clinical Study
There is an increasing demand for low‐level light therapy devices for the treatment of dermatologic conditions, such as acne, hair loss, undesirable body hair, and skin aging. This study evaluated the safety and effectiveness of a novel hand‐held low‐level light therapy device with a 680 nm red laser diode and a 450 nm blue light‐emitting diode for the treatment of mild‐to‐moderate acne. A prospective clinical study was conducted on 57 patients with mild‐to‐moderate acne and Fitzpatrick skin types II–IV. Treatments were self‐administered by the patients at home daily for 4 weeks. Conventional treatment was restricted during the study period. The number of inflammatory and noninflammatory lesion counts, Investigator’s Global Assessment grade, patients’ self‐assessment, and adverse events were measured every two weeks, and follow‐ups were performed until four weeks after the final treatment. Moreover, we evaluated the bactericidal effect of low‐level light therapy on Cutibacterium acnes, a causative agent of acne vulgaris, in vitro. The mean number of inflammatory acne lesions decreased statistically at weeks 4 ( ∗∗∗p < 0.001) and 8 ( ∗∗∗p < 0.001). The proportion of Investigator’s Global Assessment grade 3, indicating moderate acne severity, decreased significantly at the final visit. No severe adverse reactions were reported. Furthermore, there was a significant reduction in the viability of Cutibacterium acnes following low‐level light therapy exposure in vitro. The results of this study demonstrate that this novel, hand‐held, and low‐level light therapy device are safe and effective for the treatment of inflammatory acne, with good adherence.
- 1 January 2023
- Published by Wiley in Dermatologic Therapy
- Vol. 2023 (1)
Open AccessA Novel, Hand‐Held, and Low‐Level Light Therapy Device for the Treatment of Acne Vulgaris: A Single‐Arm, Prospective Clinical Study
There is an increasing demand for low‐level light therapy devices for the treatment of dermatologic conditions, such as acne, hair loss, undesirable body hair, and skin aging. This study evaluated the safety and effectiveness of a novel hand‐held low‐level light therapy device with a 680 nm red laser diode and a 450 nm blue light‐emitting diode for the treatment of mild‐to‐moderate acne. A prospective clinical study was conducted on 57 patients with mild‐to‐moderate acne and Fitzpatrick skin types II–IV. Treatments were self‐administered by the patients at home daily for 4 weeks. Conventional treatment was restricted during the study period. The number of inflammatory and noninflammatory lesion counts, Investigator’s Global Assessment grade, patients’ self‐assessment, and adverse events were measured every two weeks, and follow‐ups were performed until four weeks after the final treatment. Moreover, we evaluated the bactericidal effect of low‐level light therapy on Cutibacterium acnes, a causative agent of acne vulgaris, in vitro. The mean number of inflammatory acne lesions decreased statistically at weeks 4 ( ∗∗∗p < 0.001) and 8 ( ∗∗∗p < 0.001). The proportion of Investigator’s Global Assessment grade 3, indicating moderate acne severity, decreased significantly at the final visit. No severe adverse reactions were reported. Furthermore, there was a significant reduction in the viability of Cutibacterium acnes following low‐level light therapy exposure in vitro. The results of this study demonstrate that this novel, hand‐held, and low‐level light therapy device are safe and effective for the treatment of inflammatory acne, with good adherence.
- Open Access
- 1 January 2022
- Published by Wiley in BioMed Research International
- Vol. 2022 (1) , 5479626
Relationships of Serum Homocysteine, Vitamin B12, and Folic Acid Levels with Papulopustular Rosacea Severity: A Case‐Control Study
Background. Rosacea is a chronic inflammatory skin disease with a multifactorial etiology. Recently, associations between serum homocysteine (Hcy) levels and inflammatory skin diseases, such as psoriasis and hidradenitis suppurativa, have been reported. However, no study has explored the levels of serum Hcy, folic acid, and vitamin B12 in patients with rosacea. Objective. To investigate serum Hcy, vitamin B12, and folic acid levels in patients with papulopustular rosacea (PPR), we characterized the association of these levels with PPR severity. Methods. This case‐control study included 138 PPR patients and 58 healthy controls. The serum levels of Hcy, vitamin B12, and folic acid were measured. A correlation was assessed between disease severity and serum levels of Hcy, vitamin B12, and folic acid. Results. Serum vitamin B12 and folic acid levels were significantly lower in PPR patients than in the healthy controls (p = 0.011 and p = 0.0173, respectively). Although serum Hcy levels did not significantly differ between PPR patients and healthy controls, PPR severity was positively correlated with serum Hcy levels (p < 0.001). Conclusions. Our results suggest a possible association between hyperhomocysteinemia and vitamin B12 deficiency in patients with PPR.
- 1 January 2022
- Published by Wiley in BioMed Research International
- Vol. 2022 (1) , 5479626
Open AccessRelationships of Serum Homocysteine, Vitamin B12, and Folic Acid Levels with Papulopustular Rosacea Severity: A Case‐Control Study
Background. Rosacea is a chronic inflammatory skin disease with a multifactorial etiology. Recently, associations between serum homocysteine (Hcy) levels and inflammatory skin diseases, such as psoriasis and hidradenitis suppurativa, have been reported. However, no study has explored the levels of serum Hcy, folic acid, and vitamin B12 in patients with rosacea. Objective. To investigate serum Hcy, vitamin B12, and folic acid levels in patients with papulopustular rosacea (PPR), we characterized the association of these levels with PPR severity. Methods. This case‐control study included 138 PPR patients and 58 healthy controls. The serum levels of Hcy, vitamin B12, and folic acid were measured. A correlation was assessed between disease severity and serum levels of Hcy, vitamin B12, and folic acid. Results. Serum vitamin B12 and folic acid levels were significantly lower in PPR patients than in the healthy controls (p = 0.011 and p = 0.0173, respectively). Although serum Hcy levels did not significantly differ between PPR patients and healthy controls, PPR severity was positively correlated with serum Hcy levels (p < 0.001). Conclusions. Our results suggest a possible association between hyperhomocysteinemia and vitamin B12 deficiency in patients with PPR.